Ligne de temps
Cyril Planchais
Ingénieur(e) de Recherche
19 juil. 2024
publication
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.
Lire plus11 janv. 2024
publication
Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells.
Lire plus13 déc. 2023
02 nov. 2023
publication
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells.
Lire plus25 oct. 2023
10 oct. 2023
publication
HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria.
Lire plus24 août 2023
news
New publication – Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller
Lire plus06 juil. 2023
publication
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
Lire plus14 févr. 2023
publication
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Lire plus03 févr. 2023
publication
Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
Lire plus21 déc. 2022
publication
Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters
Lire plus17 nov. 2022
publication
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Lire plus01 nov. 2022
publication
Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2.
Lire plus27 août 2022
07 juil. 2022
publication
NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections.
Lire plus04 juil. 2022
publication
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Lire plus28 juin 2022
publication
SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but critical for productive class switch recombination.
Lire plus17 juin 2022
news
New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Lire plus01 juin 2022
publication
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Lire plus27 avr. 2022
publication
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Lire plus08 avr. 2022
news
New publication – Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller
Lire plus12 mars 2022
publication
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.
Lire plus07 mars 2022
publication
Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.
Lire plus02 févr. 2022
publication
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.
Lire plus01 févr. 2022
17 sept. 2021
publication
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.
Lire plus01 sept. 2021
publication
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.
Lire plus08 juil. 2021
18 mai 2021
publication
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Lire plus18 avr. 2021
01 janv. 2021
publication
CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues.
Lire plus01 déc. 2020
02 sept. 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Lire plus24 juin 2020
publication
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.
Lire plus07 sept. 2015
07 sept. 2015
29 juil. 2015
11 mai 2015